Conference abstract · 8 Mar 2022
Conference abstractPublished 14 Apr 2014
Current ventricular assist device outcomes and future technology
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Heart failure (HF) remains to be a global problem with approximately 5.7 million individuals suffering from heart failure in the US alone. Heart transplantation has been the gold standard with good and predictable long term outcomes, but its applicability has been limited by the number of available donors. This has stimulated the advancement of mechanical circulatory support as an alternative to improve survival and quality of life in patients suffering from late stage congestive heart failure. First generation pulsatile-flow left ventricular assist devices (LVADs) were able to demonstrate improved survival to transplantation compared to the standard treatment of intra-aortic balloon pump and inotrope and improved survival in non- transplant eligible patients compared to optimal medical management. The second generation LVAD, i.e. the axial continuous- flow LVAD, has demonstrated tremendous improvement in patient survival and better durability with less complications and smaller in device size. Recent data from trails with the second generation continuous flow LVAD implanted as bridge-to- transplantation therapy demonstrate a survival rate approaching 90% at one year, similar to the heart transplantation survival. The improvement in outcomes has also been achieved in patients not eligible for transplant as destination therapy with similar survival to transplantation out to two years. The third generation centrifugal continuous-flow LVADs with noncontact bearings, have a significant improvement in technology and reduction in pump size with less device-related complications and improved patient outcomes. One of the third generation LVADs has been approved by FDA recently to be used as bridge-to- transplant therapy for heart failure patients with destination therapy approval pending and coming soon. Significant amount of intensive research is currently underway with multiple smaller devices and the possibility of driveline elimination with the transcutaneous energy transmission technology will likely further reduce the device-related complication significantly and improve patient outcomes. Minimal invasive off-pump LVAD implantation has been shown possible and will further increase the application of the mechanical circulatory support devices to an even larger patient population. The development of implantable LVADs has revolutionized the treatment of late-stage heart failure and its continuous advancement will open door to a large market of potential recipients with improved durability, cost and effectiveness.
Subjects
CardiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 30 Mar 2020
Cardiac Care 2020: Do actual medical literature depict a satisfactory view of Left ventricular assistant device and Right ventricular failure? - Issues with Management - Elio Aloia -University of Siena Viale M. Bracci 16 53100 Siena, Italy
Conference abstract · 12 Sep 2016
Survival analysis and post-operative complications after ventricular assist device implantation: Prognostic value of INTERMACS scale
Other · 20 Jul 2016
Percutaneous ventricular assist device TandemHeart in severe refractory cardiogenic shock
Review article · 18 Jul 2016
Role of percutaneous left ventricular assist devices in preventing cerebral ischemia
More from this journal
The newest in Clinical and Experimental Cardiology.
Short communication · 4 Aug 2026
An effective determination method for aortic valve replacement through minimally invasive lower median sternotomy
Conference abstract · 15 Jun 2026
Speckle Tracking Echocardiography for Early Identification of Chemotherapy-Induced Cardiotoxicity
Conference abstract · 15 Jun 2026
Coronary CT Angiography as a First-Line Diagnostic Tool for Stable Chest Pain: Clinical Outcomes from a Multicenter Study
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical and Experimental Cardiology
- SubjectCardiology
- BylineArticles whose byline prints “Allen Cheng”
- BylineArticles whose byline prints “Mark S. Slaughter”

